Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? (Q46494482)

22 December 2017

title

Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? (English)

1 reference

22 December 2017

Cesar Homero Gutiérrez-Aguirre

author

6

1 reference

22 December 2017

Olga Graciela Cantú-Rodríguez

7

1 reference

22 December 2017

David Gómez-Almaguer

8

object named as

D Gómez-Almaguer

1 reference

22 December 2017

author name string

G J Ruiz-Argüelles

1

1 reference

22 December 2017

L C Tarin-Arzaga

2

1 reference

22 December 2017

M L Gonzalez-Carrillo

3

1 reference

22 December 2017

K I Gutierrez-Riveroll

4

1 reference

22 December 2017

R Rangel-Malo

5

1 reference

22 December 2017

S Giralt

9

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

22 December 2017

Bone Marrow Transplantation

published in

1 reference

22 December 2017

volume

42

1 reference

22 December 2017

issue

1

1 reference

22 December 2017

page(s)

23-28

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1038/bmt.2008.90

exact match

0 references

cites work

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Allogeneic transplantation using non-myeloablative transplant regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

7 January 2021

Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

7 January 2021

Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

7 January 2021

The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

7 January 2021

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

7 January 2021

Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

7 January 2021

Do affluent societies have the only options for the best therapy?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.90

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.90

1 reference

22 December 2017

1 reference

22 December 2017